Plain-English translation of NCT07516886 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research study is following men after they have prostate cancer surgery to understand how early blood measurements of a protein called prostate-specific antigen (PSA) can help predict long-term cancer outcomes. Doctors will measure your PSA levels at different time points after surgery to see if low or high levels early on can tell us whether cancer is likely to return. This is an observational study, meaning researchers will simply track your normal care and test results—no experimental treatments or extra procedures beyond standard follow-up.
After prostate cancer surgery, doctors need better ways to predict which patients are at highest risk for cancer recurrence so they can plan the best follow-up care. This study aims to understand whether early PSA measurements can be a reliable warning sign, helping doctors identify who might need more intensive monitoring or additional treatment.
You likely qualify if…
You likely don't qualify if…
After your prostate surgery, you will have blood tests to measure your PSA level at 4–8 weeks after surgery (ideally at 1 month), and then at regular intervals during your first year and beyond, depending on your results. If your PSA is very low after surgery, you'll have routine blood tests every few months during the first year, then twice yearly for the next two years, and yearly after that. If your PSA is higher than expected, your doctor may order additional imaging scans and closer follow-up. Your regular cancer care will continue as planned—this study simply tracks your standard PSA measurements and outcomes over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Lithuania